LBA15 Amivantamab plus chemotherapy (with or without lazertinib) vs chemotherapy in EGFR-mutated advanced NSCLC after progression on osimertinib: MARIPOSA-2, a phase III, global, randomized, controlled trial

Antonio Passaro, Byoung Chul Cho, Yan Wang et al. · Annals of Oncology · 2023

Cited by 17 works. doi:10.1016/j.annonc.2023.10.063 Open-access PDF

Authors

References